The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.
April 19th 2024
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Investigates Potential Increased Risk of Death With Umbralisib in Select Lymphomas
The FDA has announced that they are investigating umbralisib (Ukoniq), an oral inhibitor of PI3K-delta and CK1-epsilon that is approved to treat patients with marginal zone lymphoma and follicular lymphoma, after initial data from the phase 3 UNITY-CLL trial revealed a potential increased risk of death in those who received the agent.
Acalabrutinib Shows Better Safety, Tolerability Than Ibrutinib in Relapsed/Refractory CLL
John Seymour, MD, discusses the safety of acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia, and what findings from post-hoc analyses of the ELEVATE-RR trial mean for clinical practice.
Zanubrutinib sNDA for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Accepted in China
The China National Medical Products Administration has accepted a supplemental new drug application for zanubrutinib as a treatment option for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ibrutinib Increases Risk of Select Cardiovascular AEs in Patients With Chronic Lymphocytic Leukemia
Treatment with ibrutinib in patients with chronic lymphocytic leukemia was linked with increased risk of cardiovascular adverse effects like atrial fibrillation, hospital-diagnosed bleeding, and heart failure, but was not linked with a higher risk of acute myocardial infarction or stroke.
Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL
January 14th 2022Zanubrutinib elicited a statistically significant improvement in progression-free survival vs the combination of bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.
Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL
January 12th 2022Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Dr. Seymour on the Safety of Acalabrutinib Vs Ibrutinib in Relapsed/Refractory CLL
January 10th 2022John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.